Continuing Anti-TNF Agents past 24 Weeks of Pregnancy Associated with Fewer IBD Relapses with No Increase in Adverse Fetal Outcomes

Ahmad Abu-Heija, MBBS and Editor-in-Chief Philip Schoenfeld, MD, MSEd, MScEpi FACG discuss “Benefits and Risks Associated with Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease,” by Meyer A, Neumann A, Drouin J, et al. Ann Intern Med [2022; 175(10) 1374-82].

Om Podcasten

A new monthly publication from the American College of Gastroenterology, Evidence-Based GI (EBGI) uses evidence-based methods to create abstracts and explain study results of new and important articles in the field of gastroenterology and hepatology. Listen as editors of EBGI discuss the articles they review and how the recommendations can be applied to your practice.